
Results from an ex vivo study demonstrating effects of the nonselective alpha-1 receptor antagonist doxazosin (Cardura) on ureteral contractility raises questions about the role of alpha-blocker treatment in the management of ureteral stone disease, say urologists from the University of Wisconsin.
